Group 1: Clinical Trial Results - Relay Therapeutics' zovegalisib demonstrated a median progression-free survival (PFS) of 11.1 months in heavily pre-treated patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer [1] - Median PFS was 11.2 months in patients with kinase mutations and 11.0 months in patients with non-kinase mutations [1][2] Group 2: Safety Profile - The safety profile of the 400mg BID fed regimen was consistent with previous findings from the 600mg BID fasted dose, reinforcing the drug's potential as a treatment option [2] Group 3: Stock Performance - Relay Therapeutics shares increased by 195.16% over the past 12 months, currently trading 8.6% above its 20-day simple moving average (SMA) and 30.3% above its 100-day SMA [3] - The RSI is at 60.72, indicating neutral territory, while the MACD is at 0.5310, suggesting bullish momentum [3][4] Group 4: Analyst Consensus - The stock carries a Buy Rating with an average price target of $17.20, with recent analyst actions including Guggenheim raising the target to $22.00 and Wells Fargo raising it to $15.00 [5][6] - Benzinga Edge scorecard indicates strong momentum, with a bullish score of 98.01, showing that the stock is outperforming the broader market [5] Group 5: Price Action and Support/Resistance Levels - Relay Therapeutics shares were down 1.45% at $10.21 at the time of publication, with key resistance at $11.50 and key support at $9.00 [6]

400mg BID fed is the dose used in the ongoing Phase 3 ReDiscover-2 trial, which initiated mid-2025 11.1-month median PFS in heavily pre-treated patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer Efficacy in patients with kinase and non-kinase domain mutations is similar, with median PFS of 11.2 and 11.0 months, respectively Safety and tolerability data are consistent with 600mg BID fasted data Zovegalisib has received FDA Breakthrough Therapy designation for the Phase 3 ReDiscover-2 trial popu ...

Company Overview - Relay Therapeutics has been established for nearly 10 years, focusing on precision medicine targets [2] - The company has navigated a challenging environment for biotechs over the past few years [2] Strategic Focus - Relay Therapeutics has out-licensed its lead program, an FGFR2 inhibitor, to adapt to market conditions [2] - The company has streamlined its research organization and staggered some preclinical programs [3] Key Research Initiatives - The primary focus is now on the PI3K-alpha inhibitor, zovegalisib, which is believed to be the first mutant selective inhibitor entering clinical trials [3] - There are three major opportunities identified for zovegalisib: hormone receptor positive, HER2-negative frontline and second-line metastatic breast cancer, and PI3K-alpha-driven vascular amalgamations [3]

Group 1 - Relay Therapeutics, Inc. (RLAY) shares increased by 5.4% to $10.69, with a notable trading volume, reflecting a 17.2% gain over the past four weeks [1][2] - The rise in share price is attributed to investor optimism regarding Relay Therapeutics' clinical pipeline, particularly the development of zovegalisib (RLY-2608) for advanced breast cancer [2] - The company is conducting a phase III study (ReDiscover-2) for zovegalisib in combination with AstraZeneca's Faslodex, showing potential improvements in tolerability and progression-free survival [2] Group 2 - Relay Therapeutics is expected to report a quarterly loss of $0.36 per share, a year-over-year increase of 21.7%, with revenues projected at $15.35 million, up 99.9% from the previous year [3] - The consensus EPS estimate for Relay Therapeutics has been revised 15.7% higher in the last 30 days, indicating a positive trend that may lead to price appreciation [4] - Relay Therapeutics holds a Zacks Rank of 3 (Hold), indicating a neutral outlook compared to other stocks in the Zacks Medical - Drugs industry [4]

Core Insights - The presentation at the 46th Annual TD Cowen Healthcare Conference highlighted Relay Therapeutics' focus on advancing its lead drug candidate, zovegalisib, a PI3K mutant selective molecule, as a key priority for the upcoming year [2]. Company Strategy - Relay Therapeutics has made deliberate choices over the past few years to build a strong foundation, allowing the company to concentrate its resources on zovegalisib [2]. - The company has strategically focused its research organization and staggered the entry of its preclinical programs targeting NRAS and Fabry [3]. - Relay Therapeutics out-licensed its most advanced clinical program, lirafugratinib, to extend its operational runway and focus on its core projects [3]. Industry Context - The discussion included insights into vascular malformations, which is identified as a new and significant area of interest for the company, alongside breast cancer [1].

Company Overview - Relay Therapeutics (RLAY) reported earnings in late February, indicating that spending remains high due to ongoing zovegalisib trials [1] Analyst Background - The analyst has a Master's degree in Cell Biology and extensive experience in drug discovery, which informs their investment analysis in the biotech sector [1] - The focus is on identifying promising biotechnology companies that innovate through unique mechanisms, first-in-class therapies, or platform technologies [1] Investment Approach - The investment strategy combines scientific expertise with financial and market analysis to evaluate drug candidates, competitive landscapes, clinical trial designs, and market opportunities [1] - The goal is to provide insights that help investors understand both opportunities and risks in the biotech sector, which can yield significant returns but requires careful scrutiny [1]

Summary of Relay Therapeutics FY Conference Call Company Overview - **Company**: Relay Therapeutics (NasdaqGM: RLAY) - **Key Speakers**: Sanjiv Patel (President and CEO), Peter Rahmer (Chief Corporate Development Officer), Don Bergstrom (President of R&D) Core Industry Focus - **Primary Areas of Focus**: - Vascular malformations - Breast cancer - **Key Product**: Zovegalisib, a PI3K mutant selective molecule Key Points and Arguments Financial and Strategic Positioning - Relay Therapeutics has made deliberate choices to focus capital on advancing zovegalisib, extending cash runway into 2029 [2][3] - The company outlicensed its most advanced clinical program, lirafugratinib, to concentrate on three large clinical areas: - 2nd line hormone receptor-positive, HER2-negative breast cancer - 1st line metastatic hormone receptor HER2-negative breast cancer - PI3K driven vascular anomalies [2][3] Clinical Data and Upcoming Disclosures - Upcoming data disclosures include: - 2nd-line metastatic breast cancer data at ESMO TAT in Paris [3] - Data from 57 patients on a 400 mg BID fed dose, expected to show consistency with previous data [4] - Vascular anomalies data from 20 patients at the 12-week efficacy endpoint [5][6] Vascular Malformations Insights - Vascular malformations are driven by PI3K mutations, with previous proof of concept from non-selective PI3K inhibitors [9] - The company aims to show meaningful differentiation in response rates for zovegalisib compared to existing treatments [9][10] - There are approximately 170,000 PIK3CA-driven vascular anomaly patients in the U.S., with about 100,000 in the three subtypes of interest [15][16] - The company estimates that 25,000 of these patients would seek chronic systemic therapy [17] Trial Design and Regulatory Considerations - The ReInspire trial is designed to evaluate zovegalisib across three different dose levels, with a focus on safety and tolerability [20][21] - The primary endpoint for potential accelerated approval is the objective response rate (ORR), with a target of a 20% reduction in lesion volume [25] - The company aims to exceed the response rates of existing treatments, which range from 11% to 27% [25] Safety and Tolerability - Safety and tolerability are critical, as the treatment will be chronic, starting in childhood [26][28] - The company is focused on achieving a favorable risk-benefit profile to support long-term treatment decisions [26][28] Competitive Landscape - Zovegalisib is positioned against other treatments like alpelisib and sirolimus, with a focus on differentiating its patient population and treatment approach [30][32] - The company believes that the patient populations for zovegalisib and competing treatments will not significantly overlap [30][32] Breast Cancer Developments - The company is also advancing its breast cancer programs, with plans to share data on combination therapies and trial designs [41][50] - The focus is on ensuring tolerability in long-term treatment regimens, particularly in combination with CDK4/6 inhibitors [43][55] Additional Important Insights - The company is actively enrolling patients globally in its trials and is optimistic about the progress made so far [50] - There is ongoing interest in exploring combinations with SIRD agents in the future [61] This summary encapsulates the key points discussed during the Relay Therapeutics FY Conference Call, highlighting the company's strategic focus, clinical developments, and competitive positioning in the biotech industry.

Company Overview - Relay Therapeutics is a clinical-stage biotechnology company focused on precision medicines for oncology and genetic diseases, utilizing advanced computational modeling and partnerships to develop small-molecule therapies targeting key disease pathways [5] - The company has a market capitalization of $1.9 billion and reported a revenue of $8.36 million for the trailing twelve months (TTM), with a net income loss of $297.59 million [4] Recent Developments - On February 17, 2026, Casdin Capital disclosed an increase in its holding of Relay Therapeutics by 1,662,193 shares, raising its total to 13,003,574 shares, with an estimated transaction value of $11.86 million [2][6] - The quarter-end value of Casdin's position in Relay increased by $50.81 million, reflecting both additional purchases and stock price movements [2] Financial Position - Relay Therapeutics ended 2025 with approximately $555 million in cash, cash equivalents, and investments, which is expected to fund operations into 2029 [10] - The company reported a full-year net loss of $276.5 million, with elevated research spending [10] Stock Performance - As of the last reported price, Relay shares were valued at $10.95, representing a 235% increase over the past year, significantly outperforming the S&P 500's approximately 15% gain during the same period [6] Pipeline and Future Prospects - Relay is advancing several lead candidates, including RLY-4008, RLY-2608, and RLY-1971, and is focused on small molecule therapeutics for targeted oncology and genetic diseases [7] - The company anticipates multiple data disclosures in 2026, including Phase 1 data related to PIK3CA-driven vascular anomalies and updates on breast cancer triplet strategies involving its lead asset, zovegalisib, which is currently in a Phase 3 trial for HR positive, HER2 negative metastatic breast cancer [9]

Clinical Development Risks - The company has never successfully completed any large-scale, pivotal clinical trials, which poses a significant risk to the development of its product candidates [201]. - The company may face delays in obtaining marketing approval for its product candidates if additional clinical trials or testing are required [202]. - Clinical product development is lengthy and expensive, with uncertain outcomes, and failures can occur at any stage of testing [203]. - Interim data from clinical trials may change as more participants enroll, and preliminary data should be viewed with caution until final data is available [204]. - Delays in preclinical studies, clinical trials, or regulatory approvals could significantly increase product development costs [209]. - The company may encounter difficulties in enrolling a sufficient number of eligible patients for clinical trials, which could delay regulatory approvals [210]. - The eligibility criteria for clinical trials may limit the pool of available study participants, affecting enrollment rates [211]. - The company may need to develop companion diagnostics for its product candidates, which could further complicate patient identification for clinical trials [212]. - Adverse events not seen in early studies may emerge in later clinical trials, potentially inhibiting regulatory approval or market acceptance [218]. - The company faces a high rate of attrition in clinical trials, with many product candidates failing to show the desired safety and efficacy profile [217]. - The company is developing zovegalisib in combination with other therapies, which may introduce additional risks and uncertainties in clinical trials [226]. - The company has entered into a clinical trial collaboration with Pfizer to evaluate atirmociclib in combination with zovegalisib for metastatic breast cancer [228]. Financial and Resource Constraints - The company has limited financial and human resources, which may lead to delays or forgoing opportunities with other product candidates that could have greater commercial potential [224]. - The company incurred net losses of $342.0 million, $337.7 million, and $276.5 million for the years ended December 31, 2023, 2024, and 2025, respectively, with an accumulated deficit of $2.0 billion as of December 31, 2025 [281]. - The company has no products approved for commercial sale and does not expect to generate revenue from product sales in the foreseeable future [281]. - Future capital requirements are uncertain and may increase significantly, necessitating substantial additional funding to support ongoing research and development activities [287]. - The company expects existing cash and cash equivalents to fund operations for at least the next 12 months, but future capital needs will depend on various factors including successful clinical trials and regulatory approvals [288]. - The company may need to raise up to $250.0 million through "at the market" offerings, but has not yet sold any shares under the 2024 Sales Agreement [294]. - The company expects to continue incurring significant expenses and operating losses over the next several years [281]. - The company has incurred significant operating losses since inception and anticipates continued losses for the foreseeable future due to high research and development costs and general administrative expenses [282]. Market and Competitive Landscape - The total addressable market for the company's product candidates may be smaller than estimated, adversely affecting revenue and profitability [237]. - The company faces substantial competition in the biopharmaceutical industry, particularly in structure-based drug design for cancer and genetic diseases, which may hinder its product development and commercialization efforts [240]. - Competitors may have significantly greater financial resources and expertise in R&D, manufacturing, and regulatory approvals, potentially impacting the company's market position [242]. - The commercial opportunity could be reduced if competitors develop safer, more effective, or less expensive products, or if they obtain regulatory approvals more rapidly [243]. - The uncertainty surrounding insurance coverage and reimbursement for newly approved products could limit the company's ability to market its products and generate revenue [244]. Regulatory and Compliance Challenges - The regulatory approval process for the company's novel product candidates may be more expensive and time-consuming due to their unique mechanisms of action [231]. - The company faces risks related to the acceptance of its product candidates by the medical community and patient access, which could impact commercialization [236]. - The company is conducting clinical trials outside the United States, but the acceptance of data from these trials by the FDA is uncertain [232]. - The company must navigate complex regulatory environments and potential penalties for non-compliance, which could adversely affect its business operations [251]. - Compliance with Good Clinical Practices (GCPs) is essential, and any failure in this regard could lead to unreliable clinical data and additional regulatory hurdles [252]. - The FDA requires extensive compliance for approved products, including safety reporting and adherence to cGMPs, with failure to comply potentially resulting in product recalls or marketing restrictions [344]. - The company faces risks related to regulatory approval, including ongoing obligations and potential post-market study requirements that could lead to significant additional expenses [343]. Intellectual Property Risks - The company has obtained sole ownership of certain intellectual property rights related to clinical candidates, including zovegalisib, while some patent applications remain jointly owned [304]. - The patent protection required for successful commercialization may be limited, and the lifespan of patents is generally 20 years from the filing date, which may expire before products are commercialized [305]. - The patent prosecution process is expensive and time-consuming, and the company may not be able to file all necessary patent applications in a timely manner [308]. - The biotechnology and pharmaceutical industries are characterized by extensive litigation regarding intellectual property rights, which could adversely affect the company's business [319]. - If the company is found to infringe third-party intellectual property rights, it may be required to obtain licenses on commercially unreasonable terms, which could hinder its operations [320]. - The outcome of intellectual property litigation is unpredictable and could result in substantial costs, diverting resources from core business activities [325]. Data Privacy and Regulatory Compliance - The GDPR imposes strict rules on personal data processing, with penalties for non-compliance reaching up to €20 million or 4% of total worldwide annual revenue for serious offenses, which could adversely affect the company's operations [348]. - The UK GDPR aligns with the EU GDPR but includes specific amendments, with non-compliance potentially resulting in penalties of up to £17.5 million or 4% of worldwide revenue [349]. - The adequacy decision for the EU-U.S. Data Privacy Framework allows safe data flow from the EU to U.S. companies, but its long-term validity remains uncertain, posing risks for data management [353]. - The company may face scrutiny from data protection authorities in the EEA or UK during clinical trials, which could lead to fines and negatively impact commercialization efforts [354]. - The evolving regulatory landscape may lead to increased costs for implementing data protection measures and could result in litigation or government investigations [359]. Healthcare Policy and Economic Factors - Regulatory changes and healthcare legislative reforms could adversely affect the company's ability to market its products and may lead to increased operational costs [386]. - The company anticipates that future healthcare reform measures could limit government payments for healthcare products, impacting demand and pricing pressures [386]. - The Inflation Reduction Act (IRA) includes a $2,000 out-of-pocket cap for Medicare Part D beneficiaries, which may impact the company's business depending on implementation [387]. - Proposed rules under the Global Benchmark for Efficient Drug Pricing Model (GLOBE) and Guarding U.S. Medicare Against Rising Drug Costs (GUARD) may require manufacturers to pay incremental rebates based on international benchmark prices starting in 2026 [390]. - Changes in healthcare spending and policy, including potential reductions in Medicare reimbursement, could negatively impact future profitability [392]. - The company is subject to ongoing litigation regarding the constitutionality of the IRA's Medicare drug price negotiation program, which adds uncertainty to future revenue [387].

Financial Performance - Revenue for Q4 2025 was $7.0 million, compared to $0 for Q4 2024; total revenue for 2025 was $15.4 million, up from $10.0 million in 2024[6] - Total revenue for the 12 months ended December 31, 2025, was $15,355,000, an increase from $10,007,000 in 2024, representing a 53.5% growth[18] - Net loss for Q4 2025 was $54.9 million, or $0.32 per share, compared to a net loss of $76.0 million, or $0.45 per share, in Q4 2024; total net loss for 2025 was $276.5 million, or $1.61 per share, down from $337.7 million, or $2.36 per share, in 2024[10] - Net loss for the 12 months ended December 31, 2025, was $276,479,000, compared to a net loss of $337,708,000 in 2024, reflecting a 18.1% improvement[18] - Net loss per share for the 12 months ended December 31, 2025, was $1.61, an improvement from $2.36 in 2024[18] Expenses - Research and development expenses for Q4 2025 were $55.4 million, down from $68.1 million in Q4 2024; total R&D expenses for 2025 were $261.4 million, compared to $319.1 million in 2024[8] - Research and development expenses for the 12 months ended December 31, 2025, were $261,383,000, down from $319,089,000 in 2024, a decrease of 18.1%[18] - General and administrative expenses for Q4 2025 were $12.2 million, down from $16.9 million in Q4 2024; total G&A expenses for 2025 were $56.7 million, compared to $76.6 million in 2024[9] Cash and Assets - As of December 31, 2025, cash, cash equivalents, and investments totaled $554.5 million, down from approximately $781.3 million as of December 31, 2024[5] - Cash, cash equivalents, and investments as of December 31, 2025, totaled $554,518,000, a decrease from $781,323,000 in 2024[20] - Total assets decreased to $621,331,000 as of December 31, 2025, from $871,296,000 in 2024, a decline of 28.6%[20] - Total liabilities decreased to $54,271,000 as of December 31, 2025, from $93,504,000 in 2024, a reduction of 41.9%[20] - Total stockholders' equity decreased to $567,060,000 as of December 31, 2025, from $777,792,000 in 2024, a decline of 27.0%[20] Clinical Trials and Developments - Initial Phase 1 data of zovegalisib in PIK3CA-driven vascular anomalies is expected to be announced in the first half of 2026[1] - The company anticipates presenting Phase 1/2 breast cancer data at the ESMO TAT Congress on March 16, 2026[2] - The pediatric cohort in the Phase 1 ReInspire trial for vascular anomalies opened ahead of schedule, with approximately 20 patients expected to be reported at the time of disclosure[7] - The median progression-free survival (PFS) for all patients in the Phase 1/2 ReDiscover trial was 10.3 months, with an objective response rate (ORR) of 39% among patients with measurable disease[7] - Zovegalisib has the potential to address a significant portion of the approximately 140,000 patients with HR+/HER2- breast cancer with a PI3Kα mutation in the U.S.[11] Other Comprehensive Income - Other comprehensive income for the 12 months ended December 31, 2025, was $1,724,000, compared to a loss of $795,000 in 2024[18] Share Information - Weighted average shares of common stock for the 12 months ended December 31, 2025, were 171,586,500, an increase from 142,867,800 in 2024[18]